Leanne Holes

2.2k total citations
37 papers, 911 citations indexed

About

Leanne Holes is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Leanne Holes has authored 37 papers receiving a total of 911 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 19 papers in Pathology and Forensic Medicine and 13 papers in Hematology. Recurrent topics in Leanne Holes's work include Chronic Lymphocytic Leukemia Research (29 papers), Lymphoma Diagnosis and Treatment (19 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Leanne Holes is often cited by papers focused on Chronic Lymphocytic Leukemia Research (29 papers), Lymphoma Diagnosis and Treatment (19 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Leanne Holes collaborates with scholars based in United States, United Kingdom and France. Leanne Holes's co-authors include Ian W. Flinn, Steven Coutré, Albert S. Yu, Nina D. Wagner‐Johnston, Richard R. Furman, Brian J. Lannutti, Roger Dansey, Sissy Peterman, David M. Johnson and Langdon L. Miller and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Allergy and Clinical Immunology.

In The Last Decade

Leanne Holes

34 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leanne Holes United States	18	799	565	334	256	229	37	911
Silvia Zibellini Italy	13	629 0.8×	459 0.8×	154 0.5×	223 0.9×	242 1.1×	29	761
Claudia Fazi Italy	12	583 0.7×	397 0.7×	192 0.6×	172 0.7×	368 1.6×	20	804
Alice Mohr United States	7	413 0.5×	402 0.7×	156 0.5×	195 0.8×	139 0.6×	14	627
Olga Samoilova Russia	9	574 0.7×	634 1.1×	198 0.6×	254 1.0×	179 0.8×	20	912
Alice Lynn United States	5	932 1.2×	674 1.2×	137 0.4×	281 1.1×	390 1.7×	8	990
Catriona Byrne United States	12	465 0.6×	251 0.4×	422 1.3×	518 2.0×	100 0.4×	35	807
Takashi Akasaka Japan	15	229 0.3×	323 0.6×	222 0.7×	92 0.4×	120 0.5×	45	660
Zoltán Mátrai Hungary	10	429 0.5×	289 0.5×	140 0.4×	75 0.3×	214 0.9×	30	561
Anita Szőke United States	10	1.0k 1.3×	442 0.8×	358 1.1×	536 2.1×	191 0.8×	25	1.1k
Emanuele Cencini Italy	13	262 0.3×	281 0.5×	108 0.3×	103 0.4×	218 1.0×	55	535

Countries citing papers authored by Leanne Holes

Since Specialization

Citations

This map shows the geographic impact of Leanne Holes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leanne Holes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leanne Holes more than expected).

Fields of papers citing papers by Leanne Holes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leanne Holes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leanne Holes. The network helps show where Leanne Holes may publish in the future.

Co-authorship network of co-authors of Leanne Holes

This figure shows the co-authorship network connecting the top 25 collaborators of Leanne Holes. A scholar is included among the top collaborators of Leanne Holes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leanne Holes. Leanne Holes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jabbour, Elias, Timothy P. Hughes, Richard Van Etten, et al.. (2025). CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML. Blood. 146(Supplement 1). 901–901.

Jabbour, Elias, Delphine Réa, Jörge E. Cortes, et al.. (2024). Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia. Blood. 144(Supplement 1). 6594–6594.

Fleming, Shaun, Gail J. Roboz, Amir T. Fathi, et al.. (2023). Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia.. Journal of Clinical Oncology. 41(16_suppl). e19011–e19011. 2 indexed citations

Pemmaraju, Naveen, Jacqueline S. Garcia, Jalaja Potluri, et al.. (2020). The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. Blood. 136(Supplement 1). 49–50. 22 indexed citations

Harrison, Claire, Jacqueline S. Garcia, Ruben A. Mesa, et al.. (2020). MPN-038: Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study. Clinical Lymphoma Myeloma & Leukemia. 20. S325–S325. 5 indexed citations

Horak, Friedrich, Kamal D. Puri, Bart Steiner, et al.. (2016). Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology. 137(6). 1733–1741. 27 indexed citations

Coutré, Steven, John P. Leonard, Christopher R. Flowers, et al.. (2015). Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).. Journal of Clinical Oncology. 33(15_suppl). 8532–8532. 4 indexed citations

Vos, Sven de, Nina D. Wagner‐Johnston, Steven Coutré, et al.. (2014). Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results. Blood. 124(21). 3063–3063. 10 indexed citations

Gopal, Ajay K., Brad S. Kahl, Sven de Vos, et al.. (2014). Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). Blood. 124(21). 1708–1708. 17 indexed citations

10.

O’Brien, Susan, Nicole Lamanna, Thomas J. Kipps, et al.. (2014). Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood. 124(21). 1994–1994. 22 indexed citations

11.

O’Brien, Susan, Nicole Lamanna, Thomas J. Kipps, et al.. (2013). A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).. Journal of Clinical Oncology. 31(15_suppl). 7005–7005. 41 indexed citations

12.

Vos, Sven de, Richard R. Furman, Jacqueline C. Barrientos, et al.. (2013). Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood. 122(21). 2878–2878. 18 indexed citations

13.

Gopal, Ajay K., Brad S. Kahl, Sven de Vos, et al.. (2013). Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). Blood. 122(21). 85–85. 13 indexed citations

14.

Furman, Richard R., Sven de Vos, John P. Leonard, et al.. (2013). A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Blood. 122(21). 4180–4180. 17 indexed citations

15.

Furman, Richard R., Jacqueline C. Barrientos, Jeff P. Sharman, et al.. (2012). A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 30(15_suppl). 6518–6518. 21 indexed citations

16.

Coutré, Steven, John P. Leonard, Richard R. Furman, et al.. (2012). Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study. Blood. 120(21). 191–191. 30 indexed citations

17.

Brown, Jennifer R., Thomas M. Jahn, Richard R. Furman, et al.. (2011). 5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B). Clinical Lymphoma Myeloma & Leukemia. 11. S272–S274. 1 indexed citations

18.

Flinn, Ian W., Marshall T. Schreeder, Steven Coutré, et al.. (2011). A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.. Journal of Clinical Oncology. 29(15_suppl). 3064–3064. 18 indexed citations

19.

Flinn, Ian W., Marshall T. Schreeder, Nina D. Wagner‐Johnston, et al.. (2010). A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.. Blood. 116(21). 2832–2832. 16 indexed citations

20.

Webb, Heather K., Hao Chen, Albert S. Yu, et al.. (2010). Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies. Blood. 116(21). 1774–1774. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact